Erratum: Variants of the interleukin-1 receptor antagonist gene are associated with fat mass in men (International Journal of Obesity (2009) 33 (525-533) DOI: 10.1038/ijo.2009.47));Variants of the interleukin-1 receptor antagonist gene are associated with fat mass in men

International Journal of Obesity

Volumn 33, Issue 5, 2009, Pages 525-533

  Andersson, N ^a   Strandberg, L ^a   Nilsson, S ^b   Ljungren, O ^c   Karlsson, M K ^d,e   Mellstrom D ^a   Lorentzon, M ^a   Ohlsson, C ^a   Jansson, J O ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anakinra; Dual energy X ray absorptiometry; Single nucleotide polymorphism

Indexed keywords

FAT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXPERIMENTAL ANIMAL; FRAGILITY FRACTURE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; HYPOTHESIS; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIGENE FAMILY; OBESITY; OSTEOPOROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; TANDEM REPEAT; UNTRANSLATED REGION; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALIA; MUS;

EID: 67349262040     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2009.58     Document Type: Erratum

References (34)

1. Rafiq S, Stevens K, Hurst AJ, Murray A, Henley W, Weedon MN et al. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun 2007; 8: 344-351.
2. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99: 2930-2940.
3. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104-1110.
4. Somm E, Cettour-Rose P, Asensio C, Charollais A, Klein M, Theander-Carrillo C et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006; 49: 387-393.
5. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002; 13: 323-340.
6. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 732-734.
7. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-1359.
8. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
9. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101: 8138-8143.
10. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029.
11. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545-1547.
12. Chida D, Osaka T, Hashimoto O, Iwakura Y. Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes 2006; 55: 971-977.
13. Garcia MC, Wernstedt I, Berndtsson A, Enge M, Bell M, Hultgren O et al. Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes 2006; 55: 1205-1213.
14. Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM et al. Decreased fat mass in interleukin-1 receptor antagonistdeficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 2005; 54: 3503-3509.
15. Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 2003; 198: 877-888.
16. Strandberg L, Lorentzon M, Hellqvist A, Nilsson S, Wallenius V, Ohlsson C et al. Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J Clin Endocrinol Metab 2006; 91: 2749-2754.
17. Strandberg L, Mellström D, Ljunggren Ö, Grundberg E, Karlsson MK, Holmberg AH et al. IL6 and IL1B polymorphisms are associated with fat mass in older men: the MrOS Study Sweden. Obesity (Silver Spring) 2008; 16: 710-713.
18. Lorentzon M, Mellström D, Ohlsson C. Age of attainment of peak bone mass is site specific in Swedish men - The GOOD study. J Bone Miner Res 2005; 20: 1223-1227.
19. Mellström D, Johnell O, Ljunggren Ö, Eriksson AL, Lorentzon M, Mallmin H et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21: 529-535.
20. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL et al. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003; 68: 69-78.
21. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
22. Donath MY, Storling J, Berchtold LA, Billestrup N, MandrupPoulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008; 29: 334-350.
23. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL et al. Interleukin-6-deficient mice develop matureonset obesity. Nat Med 2002; 8: 75-79.
24. Wisse BE, Ogimoto K, Morton GJ, Williams DL, Schwartz MW. Central interleukin-1 (IL1) signaling is required for pharmacological, but not physiological, effects of leptin on energy balance. Brain Res 2007; 1144: 101-106.
25. Luheshi GN, Gardner JD, Rushforth DA, Loudon AS, Rothwell NJ. Leptin actions on food intake and body temperature are mediated by IL-1. Proc Natl Acad Sci U S A 1999; 96: 7047-7052.
26. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002; 87: 1184-1188.
27. Wisse BE, Ogimoto K, Schwartz MW. Role of hypothalamic interleukin-1beta (IL-1beta) in regulation of energy homeostasis by melanocortins. Peptides 2006; 27: 265-273.
28. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF et al. Regulation of central melanocortin signaling by interleukin1 beta. Endocrinology 2007; 148: 4217-4225.
29. Lawrence CB, Rothwell NJ. Anorexic but not pyrogenic actions of interleukin-1 are modulated by central melanocortin-3/4 receptors in the rat. J Neuroendocrinol 2001; 13: 490-495.
30. Buller K, Xu Y, Dayas C, Day T. Dorsal and ventral medullary catecholamine cell groups contribute differentially to systemic interleukin-1beta-induced hypothalamic pituitary adrenal axis responses. Neuroendocrinology 2001; 73: 129-138.
31. Um JY, Lee KM, Kim HM. Polymorphism of interleukin-1 receptor antagonist gene and obesity. Clin Chim Acta 2004; 340: 173-177.
32. Carter MJ, di Giovine FS, Jones S, Mee J, Camp NJ, Lobo AJ et al. Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians. Gut 2001; 48: 461-467.
33. Lorentzon M, Swanson C, Andersson N, Mellström D, Ohlsson C. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 2005; 20: 1334-1341.
34. Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett 2006; 580: 6289-6294.